Congressional Trading Report: Rep. George Whitesides Sold Over $50K In Planet Labs Stock - Planet Labs ( NYSE:PL )
Records from August 13, 2025 indicate that Representative George Whitesides of California made a sale of Planet Labs PL, valued between $50,001 and $100,000, with the transaction dated March 27, 2025 and filed in August. As of now, Planet Labs shares are trading down 1.63% at $6.63.
Armata Posts 59 Percent Q2 Revenue Jump
Armata Pharmaceuticals ( NYSEMKT:ARMP ) , a clinical-stage biotech developing bacteriophage therapies for drug-resistant bacterial infections, released its second-quarter results on August 12, 2025. The company posted GAAP revenue of $2.2 million, beating analyst GAAP revenue estimates of $1.38 ...
This Arm Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Monday - Almonty Indus ( NASDAQ:ALM ) , ARM Holdings ( NASDAQ:ARM )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. HC Wainwright & Co. analyst Mitchell S. Kapoor initiated coverage on Crescent Biopharma, Inc.
Innoviva ( INVA ) Q2 Sales Jump 64%
Innoviva ( NASDAQ:INVA ) , a pharmaceutical company specializing in royalties and specialty therapeutics, reported second-quarter earnings on August 6, 2025. The company announced earnings per share ( GAAP ) of $0.77 on $100.3 million in revenue.
This Cisco Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Innoviva ( NASDAQ:INVA ) , Cisco Systems ( NASDAQ:CSCO )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Needham analyst Scott Berg initiated coverage on Shopify Inc.
Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth - Iterum Therapeutics ( NASDAQ:ITRM )
DUBLIN and CHICAGO, June 30, 2025 ( GLOBE NEWSWIRE ) -- Iterum Therapeutics plc ITRM ( "Iterum" or the "Company" ) , a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-drug resistant pathogens, today announced the appointment of ...
Basilea announces commercial availability of antibiotic Zevtera® ( ceftobiprole ) in the United States
Allschwil, Switzerland, May ...
Rep. George Whitesides Has Sold Up to $5.18M Worth Of Innoviva Stock: Here's What You Should Know - Innoviva ( NASDAQ:INVA )
A report on April 23, 2025 shows that Representative George Whitesides from California sale stock in Innoviva INVA, valued between $2,222,033 and $5,180,000. According to the April filing, the transaction occurred on April 23, 2025. At the time of writing, Innoviva shares are trading down 0.0% at ...
Excelerate Energy, MediaAlpha And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - American Axle & Mfg Hldgs ( NYSE:AXL ) , Alumis ( NASDAQ:ALMS )
U.S. stock futures were lower this morning, with the Dow futures falling more than 100 points on Tuesday. Shares of Excelerate Energy, Inc. EE fell sharply in today's pre-market trading. Excelerate Energy announced the pricing of upsized public offering of class A common stock.
Basilea reports strong 2024 full-year results with significant increase in revenue, profit and operating cash flow
Ad hoc announcement pursuant to Art. 53 LR ...
Basilea provides portfolio update and outlook
Allschwil, Switzerland, January ...
Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® ( ceftobiprole ) in the United States
Ad hoc announcement pursuant to Art. 53 LR ...
Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® ( ceftobiprole ) in the United States - Innoviva ( NASDAQ:INVA )
Basilea Pharmaceutica Ltd, Allschwil BSLN, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an exclusive distribution and license agreement with Innoviva Specialty ...
Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer - Xenon Pharmaceuticals ( NASDAQ:XENE )
VANCOUVER, British Columbia and BOSTON, Aug. 12, 2024 ( GLOBE NEWSWIRE ) -- Xenon Pharmaceuticals Inc. XENE, a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced the appointment of ...
Innoviva ( NASDAQ:INVA ) Upgraded to Strong-Buy by StockNews.com
StockNews.com upgraded shares of Innoviva ( NASDAQ:INVA - Free Report ) from a buy rating to a strong-buy rating in a report released on Monday. Separately, Cantor Fitzgerald initiated coverage on shares of Innoviva in a research report on Tuesday, June 18th. They issued an overweight rating ...
Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs - Innoviva ( NASDAQ:INVA )
Cantor Fitzgerald has initiated coverage on Innoviva, Inc. INVA, citing the company's unique business model centered around royalties and healthcare assets.
Innoviva Shows Rising Relative Price Performance; Still Shy Of Key Benchmark
Innoviva Shows Rising Relative Price Performance. Still Shy Of Key Benchmark Investor's Business Daily ...
Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update
LOS ANGELES, May 7, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. ( NYSE American: ARMP ) ( "Armata" or the "Company" ) , a biotechnology company focused on high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today ...
RPRX: 3 Biotech Stocks Heating up for May
Given increasing healthcare spending, rising research and development ( R&D ) in personalized medicine, several advancements in genetic engineering, regulatory support, and the rapid adoption of AI, the biotechnology industry is well-poised to witness robust growth in the foreseeable future.
Innoviva Earns IBD Rating Upgrade
In a welcome move, Innoviva ( INVA ) saw its Relative Strength Rating improve from 65 to 71 on Monday. X This proprietary rating tracks technical performance by using a 1 ( worst ) to 99 ( best ) score that indicates how a stock's price action over the trailing 52 weeks compares to other ...
Innoviva ( NASDAQ:INVA ) Upgraded by StockNews.com to "Buy"
StockNews.com upgraded shares of Innoviva ( NASDAQ:INVA - Free Report ) from a hold rating to a buy rating in a report released on Friday. Separately, TheStreet raised Innoviva from a c rating to a b- rating in a report on Thursday, February 29th.
Innoviva ( NASDAQ:INVA ) Rating Lowered to Hold at StockNews.com
StockNews.com lowered shares of Innoviva ( NASDAQ:INVA - Free Report ) from a buy rating to a hold rating in a research report sent to investors on Thursday. Separately, TheStreet raised Innoviva from a c rating to a b- rating in a research report on Thursday, February 29th.
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update
LOS ANGELES, March 21, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. ( NYSE American: ARMP ) ( "Armata" or the "Company" ) , a biotechnology company focused on high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, ...
UTHR: 3 Biotech Stocks to Jumpstart Your Portfolio Gains
The biotech industry thrives due to consistent innovations and sustained demand for cutting-edge drugs and therapies. The sector is capitalizing on an aging population and the growing demand for effective treatments for both uncommon and prevalent illnesses, thereby contributing to its promising ...
Acinetobacter Pneumonia Therapeutics Market to Reach USD 927.1 Million to 2031
Jersey City, NJ, March 07, 2024 ( GLOBE NEWSWIRE ) -- InsightAce Analytic Pvt.
Pneumonia Therapeutics Market Forecasted to Grow at a CAGR of 7.3% by 2031, Reaching a Total Worth of USD 5.7 billion | Transparency Market Research, Inc.
Wilmington, Delaware, United States, Feb. 19, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The pneumonia therapeutics market was valued at US$ 3.0 billion in 2022. A CAGR of 7.3% is projected from 2023 to 2031, reaching over US$ 5.7 billion by 2031.
VRTX: 3 Safe Biotech Stocks to Buy This Week
With the rising prevalence of chronic diseases worldwide, increased healthcare spending, favorable government policies and funding, and growing adoption of advanced technologies, demand for innovative drugs and treatments has been rising considerably, boosting the biotech industry's outlook.
Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update
LOS ANGELES, Nov. 14, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. ( NYSE American: ARMP ) ( "Armata" or the "Company" ) , a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced ...
AMGN: November Buy Alert: 3 Biotech Stocks Making Gains
The biotech industry is well-positioned for steady growth, owing to rapid advancements in drug developments and the growing impact of chronic diseases.
Innoviva ( NASDAQ:INVA ) Stock Rating Upgraded by StockNews.com
Innoviva ( NASDAQ:INVA - Get Free Report ) was upgraded by equities researchers at StockNews.com from a "hold" rating to a "buy" rating in a report released on Friday. Separately, TheStreet downgraded Innoviva from a "b-" rating to a "c" rating in a research note on Friday, August 4th.
A new gonorrhea drug was developed by a non-profit foundation
G old affliction. The book of Leviticus mentions a contagious condition involving the continuous emission of semen and a painful erection. Only 2,500 years later, in the mid-20th century, did the discovery of antibiotics bring relief. But not, perhaps, for long.
A new gonorrhoea drug was developed by a non-profit foundation
A new gonorrhea drug was developed by a non-profit foundation The Economist ...
Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors
Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its ... PR ...
Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors
Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its ... Canada ...
Transforming Lymphoma Management Landscape with DLI's Disease Insights, Unmet Needs Analysis, KOL Perspectives, Epidemiology Study, and Regulatory Consulting Services | Disease Landscape Insights
Transforming Lymphoma Management Landscape with DLI's Disease Insights, Unmet Needs Analysis, KOL ... PR ...
Syphilis Disease Management- Role of DLI in Clinical Trial Management, Regulatory Consulting, and Price Reimbursement | Disease Landscape Insights
Syphilis Disease Management- Role of DLI in Clinical Trial Management, Regulatory Consulting, and Price ... PR ...
Medical Supplies Market Size is Projected to Hit USD 185.21 Billion, at a 4.5% CAGR by 2028 | Brandessence Market Research
Medical Supplies Market Size is Projected to Hit USD 185.21 Billion, at a 4.5% CAGR by 2028 | Brandessence Market ... PR ...
A Look Into Healthcare Sector Value Stocks - Innoviva ( NASDAQ:INVA ) , POINT Biopharma Global ( NASDAQ:PNT ) , First Wave BioPharma ( NASDAQ:FWBI ) , CalciMedica ( NASDAQ:CALC )
A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the ...
Active Pharmaceutical Ingredients ( API ) Market Expected to Reach USD 284.4 Billion by 2027 At a 6.4% CAGR by 2027 | Brandessence Market Research
Active Pharmaceutical Ingredients ( API ) Market Expected to Reach USD 284.4 Billion by 2027 At a 6.4% CAGR by ... PR ...
Poultry Health Market Size is Expected to Reach USD 6.00 billion by 2025, with a CAGR of 6.79% over forecasted period| Brandessence Market Research
Poultry Health Market Size is Expected to Reach USD 6.00 billion by 2025, with a CAGR of 6.79% over forecasted ... PR ...
Viral Vector Manufacturing Market to Grow Substantially by 2029- Brandessence Market Research
LONDON, Sept. 14, 2023 /PRNewswire/ -- According to a comprehensive research report by Brandessence Market Research ( BMRC ) , "Viral Vector Manufacturing Market Size, Share Outlook Growth By Top Company, Development, Application, Segmentations, Trends And Forecast 2021-2029."
Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update
LOS ANGELES, Aug. 14, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. ( NYSE American: ARMP ) ( "Armata" or the "Company" ) , a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced ...
Untreatable Gonorrhea threat has drugmakers sprinting for new cures
A rise in gonorrhea infections has drugmakers racing to develop new therapies as the sexually transmitted infection increasingly evades the last medication that can effectively treat it.
StockNews.com Downgrades Innoviva ( NASDAQ:INVA ) to Hold
Innoviva ( NASDAQ:INVA - Get Free Report ) was downgraded by StockNews.com from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Friday. Other research analysts have also issued research reports about the company.
Overview Of Value Stocks In The Healthcare Sector - Innoviva ( NASDAQ:INVA ) , AcelRx Pharmaceuticals ( NASDAQ:ACRX ) , Organon ( NYSE:OGN ) , Dynavax Technologies ( NASDAQ:DVAX ) , Allarity Therapeutics ( NASDAQ:ALLR )
A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the ...
Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics
Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage ... PR ...
Independent Proxy Advisory Firm ISS Recommends Alkermes Shareholders Vote Against Sarissa Employees' Election to Alkermes Board
Independent Proxy Advisory Firm ISS Recommends Alkermes Shareholders Vote Against Sarissa Employees' Election ... PR ...
AstraZeneca-Spin Off Entasis Secures FDA Approval For First Pathogen-Targeted Therapy Addressing Acinetobacter - Innoviva ( NASDAQ:INVA )
Innoviva Inc's INVA affiliate Entasis Therapeutics Inc received FDA approval for Xacduro ( sulbactam and durlobactam for injection ) , co-packaged as a treatment for hospital-acquired pneumonia.
FDA approves Innoviva's bacterial pneumonia treatment
The Food and Drug Administration said Tuesday that it approved Innoviva's Xacduro pneumonia treatment, which fights the Acinetobacter bacteria.
Over $125M Bet On Occidental Petroleum? Check Out These 4 Stocks Insiders Are Buying - Innoviva ( NASDAQ:INVA ) , DISH Network ( NASDAQ:DISH )
Although US stocks closed higher on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
